化浊行血兼以温阳法治疗代谢综合征的临床和实验研究
|
摘要
目的:系统阐述血浊的理论体系,通过临床研究和实验研究探讨化浊行血兼以温阳法治疗代谢综合征的作用机制,为临床辨证施治提供新的思路和方法。方法:临床研究将65例代谢综合征患者随机分为化浊行血汤加淫羊藿治疗组(33例)和罗格列酮对照组(32例),疗程为8周,分别观察各组的临床症状疗效,中医症候疗效,腰围、腰臀比、体重及体重指数疗效,血脂、血糖、血压、空腹胰岛素及胰岛素抵抗指数疗效。实验研究将将32只雄性SD大鼠随机分为对照组、模型组、中药组及西药组,对照组给于基础饲料,其余三组给于高脂高盐饮食,连续喂养8周造模成功后中药组给于化浊行血汤加淫羊藿,西药组给于罗格列酮,对照组和模型组给于生理盐水各治疗4周,各组治疗期间饮食同前,分别观察各组体重、血脂、血糖及胰岛素抵抗指数、瘦素、血清TNF-α及内脏脂肪水平变化。结果:临床研究表明化浊行血汤加淫羊藿能明显改善代谢综合征患者临床症状,降低胆固醇和血压水平,减轻腰围、腰臀比、体重及体重指数,效果优于罗格列酮;而罗格列酮在降低甘油三酯方面则优于化浊行血汤加淫羊藿。实验研究表明化浊行血汤加淫羊藿与罗格列酮均能明显降低MS大鼠血脂、血糖、TNF-α及LP水平,改善胰岛素抵抗;化浊行血汤加淫羊藿可有效降低MS大鼠体重及内脏脂肪,且作用明显优于罗格列酮。结论:阳虚血浊是MS的基本病机,化浊行血汤加淫羊藿可明显改善MS患者胰岛素抵抗、腹型肥胖、糖脂代谢及血压异常;其作用机制可能是减轻体重、减少内脏脂肪、调节脂肪因子、控制炎症状态及改善胰岛素抵抗。
Objective: Completely expounded the theoretical system of blood turbidity, Through the observation of clinical and experimental research, this study is primarily to discuss the mechanism of treating Metabolic syndrome by the method of eliminating the turbidity in blood and warming yang, provide a new way for treating MS. Methods: In clinical observation, 65 cases were divided into two groups, they are group of taking orally Huazhuoxingxue Tang and Epimedium (33 cases), group of taking orally Rosiglitazone (32 cases). The treatment course of each group is eight weeks. We observed the change of Clinical symptom , TCM syndrome, waist, waist-hip ratio, weight and body mass index, blood fats, blood sugar, blood pressure, fasting insulin and insulin resistance index of each group. In experimental research, 32 male Sprague Dawley rats were randomly divided into four groups: Chinese medicine-treated group, western medicine-treated group, model group and control group. The control group were feed basic diet, and the rest groups were established to be insulin resistance models with feeding high-fat-salt diet in 8 weeks. Then the Chinese medicine-treated group were treated with HuazhuoxingxueTang and Epimedium, the western medicine-treated group with Rosiglitazone, the model group and the control group with physiological saline. The treatment course of each group is four weeks. We observed the change of body weight, blood fats, blood sugar and insulin resistance index, leptin, TNF-αand internal fat level of each group. Results: The treatment of taking orally Huazhuoxingxue Tang and Epimedium can more effectively improve clinical symptom, reduce the blood pressure , the blood cholesterol, the waist, the waist-hip ratio, the weight and body mass index level than taking orally Rosiglitazone, and in the other hand taking orally Rosiglitazone more effectively than taking orally Huazhuoxingxue Tang and Epimedium in reducing triglyceride level. The experimental research tell us that both of Huazhuoxingxue Tang and Epimedium and Rosiglitazone can effectively improve insulin resistance, reduce blood fats, blood sugar, TNF-αand leptin level of MS model rats, taking orally Huazhuoxingxue Tang and Epimedium can more effectively reduce body weight and internal fats than Rosiglitazone. Conclusion: The syndrome of blood turbidity and deficiency of Yang is the basic TCM pathogenesis of MS, Huazhuoxingxue Tang and Epimedium has improving effect on glucose and lipid metabolism, insulin resistance , central obesity, and abnormalities of blood pressure; and its mechanisms may be: reducing body weight and internal fats, regulating above adipocytokines, controlling inflammational state in the body and improving insulin resistance.
Objective: Completely expounded the theoretical system of blood turbidity, Through the observation of clinical and experimental research, this study is primarily to discuss the mechanism of treating Metabolic syndrome by the method of eliminating the turbidity in blood and warming yang, provide a new way for treating MS. Methods: In clinical observation, 65 cases were divided into two groups, they are group of taking orally Huazhuoxingxue Tang and Epimedium (33 cases), group of taking orally Rosiglitazone (32 cases). The treatment course of each group is eight weeks. We observed the change of Clinical symptom , TCM syndrome, waist, waist-hip ratio, weight and body mass index, blood fats, blood sugar, blood pressure, fasting insulin and insulin resistance index of each group. In experimental research, 32 male Sprague Dawley rats were randomly divided into four groups: Chinese medicine-treated group, western medicine-treated group, model group and control group. The control group were feed basic diet, and the rest groups were established to be insulin resistance models with feeding high-fat-salt diet in 8 weeks. Then the Chinese medicine-treated group were treated with HuazhuoxingxueTang and Epimedium, the western medicine-treated group with Rosiglitazone, the model group and the control group with physiological saline. The treatment course of each group is four weeks. We observed the change of body weight, blood fats, blood sugar and insulin resistance index, leptin, TNF-αand internal fat level of each group. Results: The treatment of taking orally Huazhuoxingxue Tang and Epimedium can more effectively improve clinical symptom, reduce the blood pressure , the blood cholesterol, the waist, the waist-hip ratio, the weight and body mass index level than taking orally Rosiglitazone, and in the other hand taking orally Rosiglitazone more effectively than taking orally Huazhuoxingxue Tang and Epimedium in reducing triglyceride level. The experimental research tell us that both of Huazhuoxingxue Tang and Epimedium and Rosiglitazone can effectively improve insulin resistance, reduce blood fats, blood sugar, TNF-αand leptin level of MS model rats, taking orally Huazhuoxingxue Tang and Epimedium can more effectively reduce body weight and internal fats than Rosiglitazone. Conclusion: The syndrome of blood turbidity and deficiency of Yang is the basic TCM pathogenesis of MS, Huazhuoxingxue Tang and Epimedium has improving effect on glucose and lipid metabolism, insulin resistance , central obesity, and abnormalities of blood pressure; and its mechanisms may be: reducing body weight and internal fats, regulating above adipocytokines, controlling inflammational state in the body and improving insulin resistance.
引文
[1]王新陆.脑血辨证.北京.中国医药科技出版社,2002:82～991.
[2]王新陆.论血浊与脑病.山东中医杂志,2006 ,25 (9):5791.
[3]王新陆.血浊证的辨证治疗.山东中医杂志2007,26 (1):3～5.
[4]蔡能.心身疾病.精神医学丛书.第二卷长沙.湖南出版社,1985: 551.
[5]朱文昊,王中琳.血浊的病因病机探讨.中外健康文摘,2007(1):67～68.
[6]王斌胜,王栋先.血浊致病浅析.中外健康文摘·医药学刊,2008,5(2):123.
[7]郭明冬.“浊邪”新论.中国中医基础医学杂志,2006,(12):805~807.
[8]许筱颖.浊毒致病理论初探.辽宁中医杂志,2007,(34):28~29.
[9]唐启盛.“浊毒痹阻脑络”对老年期痴呆的影响.北京中医药大学学报,1997,20(6):24.
[10]王威,江海涛,李玉红,等.论“疏肝导浊”法对脂肪肝的治疗.中医研究, 2006,19(5):2~4.
[11]战丽彬,牛新萍.论脂浊致病.中华中医药学刊,2007,25(6):1103~1105.
[12]唐雪梅.浊邪及其致病机理探讨.辽宁中医杂志,2006,33(11):1416~1418.
[13]张泽,杨关林.冠心病从痰瘀论治的中西医理论探析.中国医药科学,2005, 2(2):37~38.
[14]张哲,刘君,祖晶.杨关林教授治疗老年胸痹心痛撷英.中医药学刊,2002,21(4):579~580.
[15]李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医,2004, 22(1):17.
[16]蒉纲,黄燕兴,毛旭明,等.清浊化瘀方为主治疗痛风性关节炎——附43例疗效分析.中医文献杂志,2005,(2):42.
[17]李佃贵,王燕云,陈烯.解毒化浊法结合微观检测治疗慢性萎缩性胃炎.北京中医药大学学报(中医临床版),2004,11(1):7.
[18]晏庆德.解毒法治疗脑中风急性期机理探讨.中国中医急症,2000,9(4):164.
[19]黄峻,刘超,丁国宪.代谢综合征与心血管疾病,北京:科学出版社,2004,1: 22.
[20] Tonkin A.The metabolic syndrome-a growing problem.European Heart Journal Supplements.2004;6:37.
[21]田成功,邵加庆,于镔.瘦素:胰岛素抵抗的独立危险因素.中华内分泌代谢杂志,2002,18(3):184~187.
[22] Hotamisligil GS,Peraldi P,Budavari A,et al. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-αand obesity-induced insulin Resistanee [J].Scienee, 1996,271(5249):665~668.
[23] Ridker PM,Buring JE,Cook NR,et al.C-reactive protein,The metabolic syndrome,and risk of incident cardiovascular events:an 8-year follow-up of 14719 initially healthy American women.Circulation,2003,107(3):391~397.
[24] Boden G,She P,Mozzoli M,et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor pathway in rat liver.Diabetes,2005,54(12):3458~3465.
[25] Kovacs P,Stumvoll M.Fatty acids and insulin resistance in muscle and live.Best Pract Res Clin Endocrinol Metab,2005,19(4):625~635.
[26]王维敏,马向华.代谢综合征患者瘦素抵抗的研究.医学研究生学报,2004,17(7):610~612.
[27] Nelly Pitteloud,Vamsi K Mootha,Andrew A Dwyer,Megan Hardin,et al. Relationship Between Testosterone Levels,Insulin Sensitivity,and Mitoehondrial Function in Men Diabetes Care.2005,28(7):1636~1642.
[28] Giagulli VA,Kaufman JM,Vermeulen A. Pathogenesis of the deereased androgen levels in obese men. J Clin Endocrinol Metab,1994,79:997~1000.
[29] Katznelson L,Rosenthal DI,Rosol MS,Anderson EJ,Hayden DL, Schoenfeld DA,Klibanski A. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism.A JR Am J Roenigenol,1998;170(2):423~427.
[30] Pritchard J,DesPres JP,Gagnon J,Tehemof A,Nadeau A,Tremblay A, Bouehard C.Plasma adrenal,gonadal,and conjugated steroids before and after long-term over feeding in identical twins.Clin Endocrinol Metab 1998;83(9):3277~3284.
[31] Marin P,Oden B,Bjorntorp P. Assimilation and mobilization of triglycerides insubertaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens.Clin Endoerinol Metab,1995,80(l):239~243.
[32] Cohen PG.The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity.Med Hypotheses 1999,52:49~51.
[33] Khaw KT,Barrett Connor E. Lower endogenous androgens Predict central adiposity in men. Ann Epidemiol ,1992,2:675~682.
[34] Tsai EC,Boyko EJ,Leonetti DL,Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord ,2000,4:485~491.
[35]梁春红,李小鹰,楚新梅.雄激素受体及雄激素在老年男性高血压患者中的变化及意义.中国分子心脏病学杂志,2006;6:191~193.
[36] Johan,Svartberg,et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Troms study European Journal of endoerinology ,2004,150:65~71.
[37]吴水生,叶钦勇,林求诚.中老年男性性激素水平与不同肾虚证型关系研究.福建中医药,2000,31(2):3.
[38]叶钦勇.中老年男性肾虚患者性激素与血脂关系研究.福建中医药,1999,30(4):1.
[39]金文胜,潘长玉.国际糖尿病联盟关于代谢综合征定义的全球共识.中华内分泌代谢杂志,2005,21(4):4b~1~4b~2.
[40]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002:386.
[41]胡仁明.内分泌代谢病临床新技术.北京:人民军医出版社, 2002:443.
[42] Chen H.Cellular inflammatory responses:novel insights for obesity and insulin resistance.Pharmacol Res,2006,53(6):469~477.
[43] Greenberg AS,Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr,2006,83(2):4615~4655.
[44] Xu H,Barnes GT,Yang Q,et al.Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.J Clin invest,2003,112:1821~1830.
[45] Lacasa D,Taleb S,Keophiphath M,et al. Macrophage-secreted factors impair human adipogenesis : involvement of Proinflammatory state in preadipocytes. Endocrinology,2007,148(2):868~877.
[46] Maachi M,Pieroni L,Bruckert E,et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF alpha,leptin and IL-6 levels in obese Women. Int J Obes Relat Metab Disord,2004,28(8):993~997.
[47] Weisberg SP,Mccann D,Desai M,et al. Obesity is a ssociated with macrophage accumulation in adipose tissue.J Clin Invest,2003,112:1796~1808.
[48] Cancello R,Clement K. is obesity an inflammatory illness?Role of low-grade inflammation and macrophage infiltration in human white adipose tissue.Bjog,2006,113(10):1141~1147. [49 ]《中医大辞典》编辑委员会编.中医大辞典(中药分册).北京:人民出版社,1980:2862
[50]黄阿根,钱建亚,谭道经,等.荷叶黄酮提取工艺研究.食品与机械,2000, 79 (5):14~16.
[51]杜力军,孙虹,李敏,等.荷叶大豆及其合剂调脂活性部位的研究.中草药, 2000,31 (7):526~528.
[52]许腊英,毛维纶,江向东,等.荷叶降血脂的开发研究.湖北中医杂志, 1996, 18(123): 42~43.
[53]李仪奎,姜名瑛主编.中药药理学.北京:中国中医药出版社,1992:127,181~182.
[54]陈红宾,江京俐,于兰.4种山楂属植物的药理作用及其LD50比较.中国中药杂志,1994;19(8):454~455.
[55]孙翠玉.山楂的研究进展.中国基层医药,2001 (5):53~54.
[56]李贵海,孙敬勇,张希林,杨振宁,周超,杨书斌.山楂降血脂成分的实验研究.中草药.2002,33(1):50~52.
[57]李国湟等.国产益心酮治疗冠心病心绞痛45例疗效观察.山西医药杂志,1986,15(3):183~185.
[58] Koshioka N,Hotta N,Ishii Y,et al. Studies on the evaluation of crude drugquantitativeⅡestimation of anthraquinone in cassia seeds.生药学杂志,1978,32(3):168.
[59] Hye SYC . Potential inhibitors of platelet aggregation from plant source anthraquinones from seeds of Cassia obtusifolia and related compound. Nat Prod ,1990,53 (3):630.
[60]谢艳华,王四旺,郭倩.中药水蛭抗炎作用的实验研究.第四军医大学学报,1996,17(60:431.
[61]冯玲玲,马金保.溶栓胶囊的研制及临床应用.中草药,1997,28(9):558.
[62]王冬梅,尚丽彤,翟路.大黄的研究进展.现代商贸工业,2008,20(2): 286~287.
[63]李红江,陈德昌.大黄对烫伤大鼠粘膜上皮细胞肿瘤坏死因子受体基因表达的影响.中国急救医学,2001,21(1):1~3.
[64]徐先祥,夏伦祝,高家荣,等.黄芪总苷和赤芍总苷协同抗血小板作用研究[J].中药材, 2002, 25(9): 653~655.
[65]吴家斌,舒贵扬.赤芍801对肾病综合征患者血脂和血液流变学的影响.中药药理与临床,2001;17(1):45~6.
[66] Hsu FL, Lai CW, Cheng JT. Antihyperglycemic effects of paeoniflorin and 8-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora.Planta Med, 1997;63(4):323~5.
[67]骆苏芳,张佩文,李锐松.虎杖结晶4号对兔血管的舒张作用.第一军医大学学报,1992,12(1):10.
[68]王跃忠,骆苏芳,张佩文,等.3,4,5-三羟基芪-3-D-葡萄糖甙减轻动脉内皮损伤性血栓形成的作用[J].中国药理学报,1995,16(2):159.
[69]上海医药工业研究所中药分析室.虎杖综合利用.医药工业,1976,10:34.
[70]木岛正夫.药用植物大辞典(日) .广川书店,1977:28.
[71]徐承水,王文房.何首乌提取物对大鼠血脂水平的影响.曲阜师范大学学报, 2004,30(3): 85.
[72]徐承水.何首乌提取物对家兔红细胞膜磷脂成分及电泳率的影响.上海中医药大学学报,2000,14(3):57.
[73]刘铁汉,王本样,王毅,等.淫羊藿苷及其肠菌代谢产物对THP-1细胞分泌细胞因子的影响.药学学报,2000,35(4):245~248.
[74]许兰芝,等.淫羊藿总黄酮对肾上腺素能受体阻断作用的研究.中国药理学通报,1994;10(4):311.
[75]王敏,等.淫羊藿甙对血管平滑肌的作用.沈阳药科大学学报,1993;10(3):185.
[76]李锐松,许俊杰.淫羊藿煎剂对健康人血小板聚集性的影响.中药药理与临床,1987;4(4):45~48.
[77]葛淑兰,田景振.淫羊藿及其有效成分的药理研究进展.中国药师,2005, 8(6):462~464.
[78]徐长春,李晓宇,杨军平,等.荷叶生物总碱对肥胖高脂血症大鼠减肥作用的实验研究.江西中医学院学报,2001,23(3):120~121. [79 ]阎君宝,金龙,汪江碧,等.决明子抑制营养性肥胖大鼠体重增加的作用.中药材,2001,27 (4) :281～284.
[80]高小平.中药提取物中α2葡萄糖苷酶抑制剂的筛选.天然产物研究与开发, 2003, 115 (6)∶5 36.
[81]周亚兵.酸味中药复方对2型糖尿病大鼠糖代谢的调节作用.成都中医药大学学报,2004,27 (1)∶1 3
[82] Carey DG.Abdominal obesity.Curr Opin Lipidol,1998,9:35.
[83] Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. ORev, 2000,1(1): 47.
[84]黄峻,刘超,丁国宪.代谢综合征与心血管疾病,北京:科学出版社,2004,1:22.
[85] Lithell HL,Hyperinsulinemia,insulin resistence and treatment of hypertension. Am J HyPertention.1996,9:1508~1548.
[86] Tonkin A.The metabolic syndrome~a growing problem.European Heart Journal Supplements.2004,6:37.
[87] Yoshikawa H,Tajiri Y,Sako Y,et al.Effects of free fatty acidsonβcell functions:a possible involvement of peroxisome proliferators activated receptors or pancreaticduodenal homeobox.Metabolism,2001,50:613~618.
[88] Mu YM,Yanase T,Nishi Y,et al.Saturated FFA,palmiti-acid and stearic acid,induce apoptosis in human granulosacells.Endocrinology,2001,142:3590~3597.
[89] Tripathy D,Mohanty P,Dhindsa S,et al.Elevation of free fatty acids induces inflammation and impairs vascular reactivity inhealthy subjects.Diabetes,2003,52:2882~2887.
[90] Burke JR.Targeting I kappa B kinase for the treatment of inflam-matory and other disorders.Curr Opin Drug Discov Devel,2003,6:720~728.
[91] Sun Y,Liu S,Ferguson S,et al.Phosphoenolpyruvate carboxyki-nase overexpression selectively attenuates insulin signaling andhepatic insulin sensitivity in transgenic mice.J Biol Chem,2002,277:23301~23307.
[92]李卫菊.脂肪因子和代谢综合征.中国分子心脏病学杂志,2007,7(6):366~368.
[93] Van Dielen FM,Van Veer C,Buurman WA,et al. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab,2002,87(4):1708~1716.
[94] Ailhaud G.Adipose tissue as a secretory organ:from adipogenesis to the metabolic syndrome. Comptes Rendus Biologies,2006,32 (8):570~577.
[95] Frühbeck G,Salvador J.Role of adipocytok ines in metabolism and disease.Nutrition Research,2004,24 (10):803~826.
[96] Koh KK,Han SH,Quon MJ. Inflammatory Markers and the Metabolic Syndrome Insights From Therapeutic Interventions.Journal of the American College of Cardiology,2005,46 (11):1978~1985.
[97] Takeshita Y,Takamura T,Hamaguchi E,etal. Tumor necrosis factor-αinduced production of plasm inogen activator inhibitor-1 and its regulation by pioglita zone and cerivastatin in a nonmalignant human hepatocyte cellline.Metabolism,2006,55 (1):1464~1472.
[98] Gonzalez MA, Selwyn AP.Endothelial function, inflammation, and prognosis in cardiovascular disease .The American Journal of Medicine,2003,115 (8): 99~106.
[99] Black PH. The inflammatory consequences of psychologic stress:Relationship toinsulin resistance,obesity,atherosclerosis and diabetes mellitus,type II. Medical Hypotheses,2006,67 (4):879~891.
[100] Yudkin JS,Juhan-Vague I,Hawe E,etal. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease:the HIFMECH study. Metabolism,2004,53 (7):852~857.
[1]刘振平.运动和代谢综合征.中国运动医学杂志,2000,19(2):191.
[2] Tsujinaka K,Nakamura,T Imaeda H,et al. A high lipid Peroxide diet feeding facilities normal rats to insulin resistance andβcell apoptosis.Diabetes,2000,49(suppl 1):A420:1773~po.
[3]程桦.代谢综合征的临床研充进展.新医学,2000;(5) 330~332.
[4] The European Group for the Study of Insulin Resistance (EGIR) .Frequeney of the WHO metabolic syndrome in European cohorts,and an alternative definition of an insulin resistance syndrome.Diabetes Metab,2002,2:354~376.
[5] World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its complication.WHO/NCD/NCS,1999:31~32.
[6] Expert Panel on Detection,Evaluation,and Treatment o f High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program(NCEP) expert panel on detection,evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) .JAMA,2001,285:2486~2497.
[7]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议.中华糖尿病杂志,2004,12(3):156~16.
[8]金文胜,潘长玉.国际糖尿病联盟关于代谢综合征定义的全球共识.中华内分泌代谢杂志,2005,21(4):4b~1~4b~2.
[9]脑卒中、冠心病发病危险因素进一步研究协作组.中国11个省的代谢综合征流行病学调查.中华预防医学杂志,2002,36(5):298.
[10] Anand SS,Yi Q,Gerstein H,et a1.Re1ationship of metabo1ic syndrome and fibrinolytic dysfunction to cardiovaseular disease.Cireulation,2003,108:420~425.
[11] Ford ES,Giles WH,Dietz WH.Prevalence of the metabolic syndrome among us adults:finds from the Third National Health and Nutrition Examination Survey JAMA,2002,287:356~359.
[12]陈蕾,贾伟平,陆俊茜,等.上海市成人代谢综合征流行病学调查.中华心血管病杂志,2003,31:909~912.
[13]孙国祥,周正元,吴国强,等.苏州地区居民代谢综合征流行病学调查.中国慢性病预防与控制,2006,4(3):215~216.
[14]顾东风,Reynolds K,杨文杰,等.中国成年人代谢综合征的患病率.中华糖尿病杂志,2005,13(3):181~186.
[15]朱致惠,汤泰秦.代谢综合征的流行病学调查与分析.暨南大学学报(医学版), 2003,24(2):66~70.
[16]宋克群,李幼阳,肖王兰,等.北京地区老年男性干部人群代谢综合征的流行病学研究.中国老年学杂志,2005,25(10):1150~1152.
[17]张红叶,史秀忠,孙凯,等.代谢综合征患病率及分布特点——青岛港健康研究.高血压杂志,2003,11(1):77~80.
[18]于桂兰,崔会娣,胡国薇.老年代谢综合征患病现状及特点.中国自然医学杂志2005,7(3):196~198.
[19] Storlien LH.Dietary fats and insulin action.16thIDF Congress Abstract and Symposium.1997,Helsinki,Finlnad,P65.
[20]贾伟平,项坤三,陆俊茜,等.局部脂肪及内分泌脂肪调节激素对瘦素水平的影响.中华内分泌代谢杂志,2000,16:70~73.
[21] Burnner EJ,Wunsch H,Marmot MG,What is an opitional diet? Relationship of marcronutirent intake to obesity, glucose toleranee,lipoprotein cholesterol leveol and the metabolic syndrome in the WhitehallⅡstudy [J].Int J Obes Relat Metab Discord,2001,25:45.
[22]祝之明.代谢综合征病因探索与临床实践.第一版.北京:人民军医出版社,2005:36.
[23] Hunt KJ,Heiss G,Sholinsky PD,et al.Familial history of metabolic disorders and the multiple metabolic syndrome:the NHLBI family heart study.Gene Epidemio,2000,19:395.
[24] Vitaliano PP,Scanlan JM,Zhang J,et al.A path model of chronic stress,the metabolic syndrome,and coronary heart disease.Psychosom Med,2002,64(3):418~435.
[25] Raikkonen K,Matthews KA,Kuller LH.The relationship between psychological risk attributes and the metabolic syndrome in healthy women : antecedent or consequence.Metabolism,2002,51(12):1573~1577.
[26]黄峻,刘超,丁国宪.代谢综合征与心血管疾病,北京:科学出版社,2004,1: 22.
[27] Lithell HL,Hyperinsulinemia,insulin resistence and treatment of hypertension. Am J HyPertention.1996;9:1508~1548.
[28] Tonkin A.The metabolic syndrome~a growing problem.European Heart Journal Supplements.2004;6:37.
[29] Stern MP . Diabetes and cardiovascular discase . The“common soil”hypothesis. Diabetes,1995,44(4):396.
[30] Neel JV. Diabetes mellitus: a thrifty genotype rendered detrimental by“progress”? Am J Hum Genet,1962,14;353.
[31] Hales CN,Barker DJP, Clark PMS,et al. Fetal and infant growth and impaired glucose tolerance at age 64,BMJ,1991,303:1019.
[32] Groop LC,et al. J Inter Med,2001,250:105.
[33] McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2diabetes.diabetes,2002,51:7.
[34] Unger RH. Minireview: weapons oflean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology,2003,144(12):5159.
[35]项坤三.代谢综合征的流行病学和病因学.国外医学·内分泌分册,2002,22(5):280.
[36] Kershaw EE,Flier JS. A dipose tissue as an endocrine organ.JClin End oerinol Metab,2004, 89:2548~2556.
[37]田成功,邵加庆,于镔.瘦素:胰岛素抵抗的独立危险因素.中华内分泌代谢杂志,2002,18(3):184~187.
[38] Arita Y ,Kihara S,Ouehi N,et al. Paradoxical decrease of an adipose~specific protein,adiPonectin, in obesity. Biochem BioPhys Res Commun.1999,257(1):79~83.
[39] Masahiro Kumada,Shinji Kihara,Noriyuki Ouchi,et al. Adiponeetin specifically Increased Tissue Inhibitor of Metalloproteinase~1 Through Interleukin~10 Expression in Human Macrophages. Circulation 2004,109:2046~2049.
[40] Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyteprotein adiponectin are decreased in parallel with reduced insulin sensitivity during theprogression to type 2 diabetes in rhesus monkeys.Diabetes,2001,50(5):1126.
[41]李东峰,杨波,杨汉东等.代谢综合征患者血清抵抗素与血脂、肥胖和胰岛素抵抗关系的研究[J〕.中国临床医学,2005,12:206~208.
[42]张艳芳,吴汉妮.抵抗素与胰岛素抵抗.国外医学分子生物学分册,2003,25(5):297~299.
[43]鲁瑾,邹大进,张家庆.肿瘤坏死因子-α致胰岛素抵抗.中国病理生理杂志,1999,15(12):1146~1148.
[44] Hotamisligil GS,Peraldi P,Budavari A,et al. IRS~1~Mediated Inhibition of Insulin RecePtor Tyrosine Kinase Activity in TNF-αand obesity~induced insulin Resistanee [J].Scienee, 1996,271(5249):665~668.
[45] Hube F,Hauner H. The role of TNF-αin Human AdiPose Tissue: Prevention of weight Gain at the ExPense of Insulin Resistance [J],Horm Metab Res,1999,31(12):626~631.
[46]顾鸣宇,盛正妍.胰岛素抵抗与脂肪肝.国外医学内分泌分册,2003,23(增刊):32~33.
[47]余丹箐,高鑫,赵耐青,等.肥胖患者血清C~反应蛋白水平变化与代谢综合征的关系.复旦学报(医学版),2002,29(1):45~49.
[48] Festa AD. Agostino R. Howard G.et al. Chronic subelinical inflammation as part of the Insulin resistance syndrome: the Insulin resistance Atheroselerosis study (IRAS). Circulation,2000,102:44~47.
[49]万惠,郭常辉,唐欣.血浆PAI~1与胰岛素抵抗及脂质紊乱相关性研究【J〕.重庆医学,2005, 34:29~32.
[50]漆泓,孙明,周宏研.MS患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系.临床内科杂志,2003,20(7):353~355.
[51] Bergman RN. Ader M. Free fatty acid and pathogenesis of type 2 diabetes mellitus. TEM,2000, 11:351~356.
[52]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议.中华糖尿病杂志,2004,(12)3:157.
[53]纪立农.国际糖尿病联盟代谢综合征全球共识定义解读.中华糖尿病杂志,2005,(13)3:176.
[54]杜鹃.有氧运动改善胰岛素抵抗综合征的研究进展.国外医学内分泌学分册,2004, 24(5):347~349.
[55] American Diabetes Association.Implication of the United Kingdom Prospective Diabetes Study.Diabetes care,1998,21:2180~2185.
[56] Stephen Smith.罗格列酮改善胰岛素抵抗和β细胞功能及对心血管的潜在保护作用.国外医学内分泌学分册,2002,22(5):284~286.
[57] Girman CJ,Rhodes T,Mercuri M,et al.The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study(4S)and the Airforce/Texas Coronary Atherosclerosis Prevention Study (ATCAPS/Tex CAPS).Am JCardiol,2004,93:136~141.
[58] Pyorala K,Ballantyne C,Lee M,et al.Reduction of coronary events by simvastatin in non–diabetic coronary heart disease patients with and without the metabolicsyndrome : subgroup analysis of the Scandinavian Simvastat in Survival Study.Diabetes,2003,52:A19.
[59] Rubins H B,Robins S J,Collins D,et al.Diabetes,plasma insulin,and cardiovascular disease : subgroup analysis from the Department of Veterans Affairs high~densitylipoprotein intervention trial(VAHIT).Arch Int Med,2002,162:2597~2604.
[60] Yusuf S,Sleight P,Pogue J,et al.Effects of an angiotensin converting enzyme inhibitor,ramipril,on cardiovascular events in high~risk patients.The Heart Outcome PreventionEvaluation Study Investigators.N Engl J Med,2000,342(3):145~153.
[61] Definition of Metabolic Syndrome Report of the National Hean,Lung,and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation,2004,109:42~46.
[62] Grundy SM,Brewer B,Clecman JI,et al.Definition of metabolic syndrome.Report of the National Heart,Lung,and Blood Institute/American Heart Association Conference on Scientific Issue Related to Definition.Circulation,2004,109:433~438.
[63]徐远.中医治疗代谢综合征的思路与方法.中医杂志,2003;44(4):301.
[64]张志玲,李惠林,张黎群,等.活血降糖饮治疗代谢综合征30例疗效观察.中医药临床杂志,2004,16(4):327~328.
[65]刘敏.2型糖尿病患者胰岛素抵抗的中医实质初探.中国中医药杂志, 2004, 2(1): 14~16.
[66]倪永骋.老年人胰岛素抵抗综合症病因病机探讨.中医药学刊,2003,21(6): 963.
[67]董卫.综合治疗胰岛素抵抗综合征56例.山西中医,2004,20(6):17.
[68]张京春,陈可冀.代谢综合征与中西医结合综合干预.中国中西医结合杂志2004;24(11):1029~1032.
[69]张晓燕,宋鲁成.试论肝脾与代谢综合征的关系.山东中医药大学学报,2005;29(1):20.
[70]胥改珍.从痰瘀论治代谢综合征.山西中医,2003,19(4):61~62.
[71]刘林,吕文亮.2型糖尿病发病机理与湿热关系的探讨,湖北中医学院学报,2004, 6(1): 29~30.
[72]于顾然,贺燕勤,郭云庚,等.冠心病中医证型于胰岛素抵抗、脂质及红细胞膜ATP酶关系的临床研究.中医杂志,2000,41(2):111~112.
[73]李东晓.痰与代谢综合征.中国中医基础医学杂志,2005,11(2):144~145.
[74]袁长武,王建清.代谢综合证中医证型与白介素~6相关性研究.新疆中医药,2008,26(2):24~28.
[75]袁肇凯,黄献平,简亚平,等.高脂血症痰瘀证候与胰岛素抵抗的关系.中国医药学报,2003,18(8):468~470.
[76]王文健.代谢综合征的中西医结合防治.中西医结合学报,2004,2(5):393,395.
[77]刘承琴,赵建群.2型糖尿病胰岛素抵抗重视从脾论治的思路.新中医,2003,35(9): 28~29.
[78]李锡杰,刘志龙.论从脾论治代谢综合征.中医药导报,2006,12(4):9~11.
[79]将卫民,唐蜀华,陈晓虎,等.高血压病辨证分型与胰岛素抵抗的初步研究.中医杂志,1999,40(1):45~46.
[80]王智明.胰岛素抵抗从肝论治的探讨.光明中医,2003,(18)6:13~14.
[81]王德玉,徐志瑛.论肝与代谢综合征.浙江中西医结合杂志,2004,14(1):23~24.
[82]董卫.综合治疗胰岛素抵抗综合征56例.山西中医,2004,20(6):17.
[83]张晓燕,宋鲁成.试论肝脾与代谢综合征的关系.山东中医药大学学报,2005, 29(1):20.
[84]杨文军,庄严.胰岛素抵抗综合征辨治初探.山东中医药大学学报,2002,26(4):275~276.
[85]张德贵,贺建丽.调肝滋肾法治疗胰岛素抵抗及其相关性疾病之临证与探讨.光明中医,2002,17(4):26~27.
[86]张慧,郭宏敏.中药养阴和瘀方对老年代谢综合征胰岛素抵抗及高凝血症的干预作用的研究.中国老年保健医学杂志,2006,4(3):50~52.
[87]吴深涛.对胰岛素抵抗宜用益肾化瘀、疏利少阳法.中医杂志,2001,42(6):332~333.
[88]张玉金,张文艺.高血压病辨证分型和胰岛素抵抗关系的探讨.河南中医,2001,21(1):36.
[89]叶子,张世珍.代谢综合征的中医认识和治疗.中国中西医结合杂志,2005;25(7): 599.
[90]王亚红,郭维琴.高脂血症中医临床研究述评[J].中国中医基础医学杂志,2001,7(10):71.
[91]梁兴伦,韩明向.胰岛素抵抗模型大鼠的中医证候研究[J].中国中西医结合杂志,2001,21(7):528~530.
[92]常宗范,冯奕超.胰岛素抵抗的中医辨证论治.吉林中医药,2001,(3):54~55.
[93]王琦,李英帅.中医对代谢综合征的认识及辨治探讨(下).浙江中医杂志,2006,41(11):623~625.
[94]肖月星,林兰,等.代谢综合征的中医认识和诊疗思路.中国中医基础医学杂志,2007;13(7):538~539.
[95]仝小林,张志远.中医对代谢综合征的认识和治疗.中医杂志,2002;43(9):708~709.
[96]熊曼琪,林安钟,朱章志,等.加味桃核承气汤对Ⅱ型糖尿病大鼠胰岛素抵抗的影响.中国中西医结合杂志,1997,17(3):165~168.
[97]蓝元隆,周国英.气虚痰浊血瘀与2型糖尿病胰岛素抵抗地关系.中国医学理论与实践,2004,(1):20.
[98]候振民,李玉明,李振有,等.“糖脂消”对代谢综合征的疗效研究.Medical Journal of the Chinese People’s Armed Police Forces,2004,15(1):15~18.
[99]潘玲,冯全生.八味丸方药对代谢综合征患者治疗效应的临床观察.四川生理科学杂志2005,27(2):87~91.
[100]管弦,黄菲,吴纪祖,等.六味地黄丸银杏叶片对早期2型糖尿病胰岛素抵抗与脂毒性的影响.辽宁中医杂志,2006,33(11):1423~1426.
[101]李莉芬,吴玉红.金芪降糖片治疗2型糖尿病胰岛素抵抗患者的观察.天津医药,2006,34(9):654~656.
[102]陈苹,朱章志,郎江明,等.益气养阴活血通腑法治疗2型糖尿病磺脲类药继发性失效的临床观察.中国中西医结合杂志,2004,11(7):585~588.
[103]于炳信.新消渴胶囊治疗2型糖尿病及胰岛素抵抗综合征的临床报告.中华现代临床医药杂志,2003,4(1):7~9.
[104]陈维铭,王馨然.半夏白术天麻汤对单纯性肥胖患者胰岛素抵抗的影响.现代中西医结合杂志,2004,13(2):351~353.
[105]喻红,邹先智.地黄饮子对改善糖尿病胰岛素抵抗的疗效观察.湖南中医药导报,2001,7(1):19.
[106]仝小林,柳红芳,朴信映,等.开郁清胃颗粒治疗Ⅱ型糖尿病胰岛素抵抗的临床研究.实用中医内科杂志,2001,15(2):10~11.
[107]袁肇凯,黄献平,田松,等.养心通脉片对胰岛素抵抗综合征血脂及甲襞微循环的影响.湖南中医学院学报,2003,23(4):35~38.
[108]刘英华,陈春梅,赖育红,等.通心络改善糖尿病冠心病患者胰岛素抵抗的观察研究.天津中医药,2006,23(4):282~283.
[109]钱秋海,庄乾竹.愈胰饮治疗胰岛素抵抗综合征的临床研究.中国中医药信息杂志,2002,9(7):12~14.
[110]卢立广,叶子,滋阴清心汤治疗代谢综合征63例观察.浙江中医杂志,2005,(3):200.
[111]安其,李朝敏,程斌.安一胶囊治疗胰岛素抵抗综合征的临床观察.成都中医药大学学报,2003,25(1):10~12.
[112]刘宪俊,杨叔禹,陈弼沧,等.平糖胶囊对气阴两虚型2型糖尿病患者胰岛素抵抗干预的研究.福建中医药,2006,37(4):3~5.
[113]谭鳗娜,林溢涛等.自拟消抵汤治疗代谢综合征30例临床观察.基层医学论坛,2006,10(4):337~338.
[114]宋镇星.调谢胶囊治疗代谢综合征疗效观察.辽宁中医杂志,2006,33(10):1294~1295.
[115]戴飞跃,黄保民,唐晨光,等.福寿降糖饮治疗2型糖尿病胰岛素抵抗的临床观察.中医药学刊.2006,24(8):1497~1498.
[116]徐云生,杜丙会.中西医结合治疗X综合征30例.山东中医杂志,1998,17(5):224.
[117]唐蜀华,蒋卫民,陈晓虎,等.针箭颗粒改善高血压病胰岛素抵抗的临床研究.中国中西医结合杂志,2000,20(7):511~514.
[118]姜淼.三黄安消胶囊治疗2型糖尿病及改善胰岛素抵抗作用的临床研究.新中医,2006,38(1):28~30.
[119]卢晓琳.益气养阴活血通腑法治疗胰岛素抵抗综合征52例.河北中医,2003,25(4):270~271.
[120]张慧,郭宏敏.中药养阴和瘀方对老年代谢综合征胰岛素抵抗及高凝血症的干预作用的研究.中国老年保健医学杂志,2006,4(3):50~52.
[121]崔琳琳,赵晓华,李丽,等.小檗碱对高脂膳食大鼠胰岛素抵抗的早期干预实验研究.中西医结合心脑血管病杂志,2005;3(3):230.
[122]林佳,潘竞锵,李博薄,等.黄连对D~半乳糖诱导大鼠血糖和糖耐量减退影响的实验研究.中国临床医药研究杂志,2005,(139):15045~15047.
[123]倪艳霞,刘安强,高云峰,等.黄连素治疗Ⅱ型糖尿病60例疗效观察及实验研究.中西医结合杂志,1988,8(12):711~712.
[124]陈其明,谢明智.黄连及小檗碱降血糖的研究.药学学报,1986,21(6):401.
[125]鲁瑾,邹大进,张家庆.黄芪预防肝瘤坏死因子-α所致胰岛素抵抗.中国中西医结合杂志,1999,19(7):420~422.
[126]李志荣.黄芪多糖冲剂治疗Ⅱ型糖尿病的临床研究.山西医药,1995,11(11):16.
[127]江清林,李延军,辛华.黄芪对胰岛素、C肽分泌作用研究.黑龙江医药科学,1999,22(3):24~27.
[128]黄春玲,吕玉萍.黄芪辅助治疗2型糖尿病对胰岛素抵抗的影响.中国中西医结合杂志,2003,23(10):779~780.
[129]黄琦,许家鸾.麦冬多糖对2型糖尿病血糖及胰岛素抵抗的影响.浙江中西医结合杂志,2002,12(2):81~82.
[130]王钦茂,刘超,赵帜平,等.丹皮多糖降血糖有效成分的筛选及其作用研究.中国中医基础医学杂志,2001,7(5):18~21.
[131]赵瑛,李蔚,祖莹.葛根素对试验性代谢综合征大鼠血脂影响的研究.中国中医药科技,2007,14(l):29~30.
[132]张妍,毕会民,甘佩珍.葛根素对胰岛素抵抗大鼠骨骼肌中蛋白激酶B表达影响.中国药理学通报,2004,20(3):307~310.
[133]李娟娟,毕会民.葛根素对胰岛素抵抗大鼠脂肪细胞葡萄糖转运蛋白4的影响.中国临床药理学与治疗学,2004,9(8):885~888.
[134]黄燕飞,刘志红,陈惠萍,等.大黄酸和罗格列酮对db/db糖尿病小鼠代谢紊乱和肾脏损伤的作用比较.肾脏病与透析肾移植杂志,2004,13(3):215~221.
[135]董卫,巫奕丽.胰岛素抵抗的针药治疗.中国临床医生, 2003, 31(1): 59.
[136]刘志诚,孙凤岷,朱苗花,等.针灸对非胰岛素依赖性糖尿病胰岛素抵抗的影响.上海针灸杂志,2000,19(1):5~7.
[137]谌剑飞,马雅玲,蔡绍华,等.针刺对糖尿病的抗凝与逆转胰岛素抵抗作用.上海针灸杂志,2001,20(4):5~7.
[138]唐胜修.头穴对中风后遗症患者胰岛素抵抗的调整作用研究.安徽中医临床杂志,~28~化瘀降浊合剂干预代谢综合征的疗效评价及其对部分致动脉粥样硬化因子的影响2002,14(3):164~165.
[139]魏群利,刘志诚.针刺配合耳穴压籽治疗2型糖尿病(肥胖型)67例.安徽中医学院学报,2002,21(3):34~37.
[140]秦福兰,贾杰,郭学军.针刺和运动疗法对2型糖尿病的疗效观察.中国针灸,2002,22(9):579~581.
[141]张智龙,薛莉,吉学群,等.针刺对2型糖尿病胰岛素抵抗影响的临床研究.中国针灸,2002,22(11):723~725.
[142]胡葵,李嘉,刘志诚.针灸治疗肥胖型2型糖尿病的临床研究.上海针灸杂志,2001,20(4):8~10.
[2]王新陆.论血浊与脑病.山东中医杂志,2006 ,25 (9):5791.
[3]王新陆.血浊证的辨证治疗.山东中医杂志2007,26 (1):3～5.
[4]蔡能.心身疾病.精神医学丛书.第二卷长沙.湖南出版社,1985: 551.
[5]朱文昊,王中琳.血浊的病因病机探讨.中外健康文摘,2007(1):67～68.
[6]王斌胜,王栋先.血浊致病浅析.中外健康文摘·医药学刊,2008,5(2):123.
[7]郭明冬.“浊邪”新论.中国中医基础医学杂志,2006,(12):805~807.
[8]许筱颖.浊毒致病理论初探.辽宁中医杂志,2007,(34):28~29.
[9]唐启盛.“浊毒痹阻脑络”对老年期痴呆的影响.北京中医药大学学报,1997,20(6):24.
[10]王威,江海涛,李玉红,等.论“疏肝导浊”法对脂肪肝的治疗.中医研究, 2006,19(5):2~4.
[11]战丽彬,牛新萍.论脂浊致病.中华中医药学刊,2007,25(6):1103~1105.
[12]唐雪梅.浊邪及其致病机理探讨.辽宁中医杂志,2006,33(11):1416~1418.
[13]张泽,杨关林.冠心病从痰瘀论治的中西医理论探析.中国医药科学,2005, 2(2):37~38.
[14]张哲,刘君,祖晶.杨关林教授治疗老年胸痹心痛撷英.中医药学刊,2002,21(4):579~580.
[15]李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治.四川中医,2004, 22(1):17.
[16]蒉纲,黄燕兴,毛旭明,等.清浊化瘀方为主治疗痛风性关节炎——附43例疗效分析.中医文献杂志,2005,(2):42.
[17]李佃贵,王燕云,陈烯.解毒化浊法结合微观检测治疗慢性萎缩性胃炎.北京中医药大学学报(中医临床版),2004,11(1):7.
[18]晏庆德.解毒法治疗脑中风急性期机理探讨.中国中医急症,2000,9(4):164.
[19]黄峻,刘超,丁国宪.代谢综合征与心血管疾病,北京:科学出版社,2004,1: 22.
[20] Tonkin A.The metabolic syndrome-a growing problem.European Heart Journal Supplements.2004;6:37.
[21]田成功,邵加庆,于镔.瘦素:胰岛素抵抗的独立危险因素.中华内分泌代谢杂志,2002,18(3):184~187.
[22] Hotamisligil GS,Peraldi P,Budavari A,et al. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-αand obesity-induced insulin Resistanee [J].Scienee, 1996,271(5249):665~668.
[23] Ridker PM,Buring JE,Cook NR,et al.C-reactive protein,The metabolic syndrome,and risk of incident cardiovascular events:an 8-year follow-up of 14719 initially healthy American women.Circulation,2003,107(3):391~397.
[24] Boden G,She P,Mozzoli M,et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor pathway in rat liver.Diabetes,2005,54(12):3458~3465.
[25] Kovacs P,Stumvoll M.Fatty acids and insulin resistance in muscle and live.Best Pract Res Clin Endocrinol Metab,2005,19(4):625~635.
[26]王维敏,马向华.代谢综合征患者瘦素抵抗的研究.医学研究生学报,2004,17(7):610~612.
[27] Nelly Pitteloud,Vamsi K Mootha,Andrew A Dwyer,Megan Hardin,et al. Relationship Between Testosterone Levels,Insulin Sensitivity,and Mitoehondrial Function in Men Diabetes Care.2005,28(7):1636~1642.
[28] Giagulli VA,Kaufman JM,Vermeulen A. Pathogenesis of the deereased androgen levels in obese men. J Clin Endocrinol Metab,1994,79:997~1000.
[29] Katznelson L,Rosenthal DI,Rosol MS,Anderson EJ,Hayden DL, Schoenfeld DA,Klibanski A. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism.A JR Am J Roenigenol,1998;170(2):423~427.
[30] Pritchard J,DesPres JP,Gagnon J,Tehemof A,Nadeau A,Tremblay A, Bouehard C.Plasma adrenal,gonadal,and conjugated steroids before and after long-term over feeding in identical twins.Clin Endocrinol Metab 1998;83(9):3277~3284.
[31] Marin P,Oden B,Bjorntorp P. Assimilation and mobilization of triglycerides insubertaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens.Clin Endoerinol Metab,1995,80(l):239~243.
[32] Cohen PG.The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity.Med Hypotheses 1999,52:49~51.
[33] Khaw KT,Barrett Connor E. Lower endogenous androgens Predict central adiposity in men. Ann Epidemiol ,1992,2:675~682.
[34] Tsai EC,Boyko EJ,Leonetti DL,Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord ,2000,4:485~491.
[35]梁春红,李小鹰,楚新梅.雄激素受体及雄激素在老年男性高血压患者中的变化及意义.中国分子心脏病学杂志,2006;6:191~193.
[36] Johan,Svartberg,et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Troms study European Journal of endoerinology ,2004,150:65~71.
[37]吴水生,叶钦勇,林求诚.中老年男性性激素水平与不同肾虚证型关系研究.福建中医药,2000,31(2):3.
[38]叶钦勇.中老年男性肾虚患者性激素与血脂关系研究.福建中医药,1999,30(4):1.
[39]金文胜,潘长玉.国际糖尿病联盟关于代谢综合征定义的全球共识.中华内分泌代谢杂志,2005,21(4):4b~1~4b~2.
[40]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社,2002:386.
[41]胡仁明.内分泌代谢病临床新技术.北京:人民军医出版社, 2002:443.
[42] Chen H.Cellular inflammatory responses:novel insights for obesity and insulin resistance.Pharmacol Res,2006,53(6):469~477.
[43] Greenberg AS,Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr,2006,83(2):4615~4655.
[44] Xu H,Barnes GT,Yang Q,et al.Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.J Clin invest,2003,112:1821~1830.
[45] Lacasa D,Taleb S,Keophiphath M,et al. Macrophage-secreted factors impair human adipogenesis : involvement of Proinflammatory state in preadipocytes. Endocrinology,2007,148(2):868~877.
[46] Maachi M,Pieroni L,Bruckert E,et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF alpha,leptin and IL-6 levels in obese Women. Int J Obes Relat Metab Disord,2004,28(8):993~997.
[47] Weisberg SP,Mccann D,Desai M,et al. Obesity is a ssociated with macrophage accumulation in adipose tissue.J Clin Invest,2003,112:1796~1808.
[48] Cancello R,Clement K. is obesity an inflammatory illness?Role of low-grade inflammation and macrophage infiltration in human white adipose tissue.Bjog,2006,113(10):1141~1147. [49 ]《中医大辞典》编辑委员会编.中医大辞典(中药分册).北京:人民出版社,1980:2862
[50]黄阿根,钱建亚,谭道经,等.荷叶黄酮提取工艺研究.食品与机械,2000, 79 (5):14~16.
[51]杜力军,孙虹,李敏,等.荷叶大豆及其合剂调脂活性部位的研究.中草药, 2000,31 (7):526~528.
[52]许腊英,毛维纶,江向东,等.荷叶降血脂的开发研究.湖北中医杂志, 1996, 18(123): 42~43.
[53]李仪奎,姜名瑛主编.中药药理学.北京:中国中医药出版社,1992:127,181~182.
[54]陈红宾,江京俐,于兰.4种山楂属植物的药理作用及其LD50比较.中国中药杂志,1994;19(8):454~455.
[55]孙翠玉.山楂的研究进展.中国基层医药,2001 (5):53~54.
[56]李贵海,孙敬勇,张希林,杨振宁,周超,杨书斌.山楂降血脂成分的实验研究.中草药.2002,33(1):50~52.
[57]李国湟等.国产益心酮治疗冠心病心绞痛45例疗效观察.山西医药杂志,1986,15(3):183~185.
[58] Koshioka N,Hotta N,Ishii Y,et al. Studies on the evaluation of crude drugquantitativeⅡestimation of anthraquinone in cassia seeds.生药学杂志,1978,32(3):168.
[59] Hye SYC . Potential inhibitors of platelet aggregation from plant source anthraquinones from seeds of Cassia obtusifolia and related compound. Nat Prod ,1990,53 (3):630.
[60]谢艳华,王四旺,郭倩.中药水蛭抗炎作用的实验研究.第四军医大学学报,1996,17(60:431.
[61]冯玲玲,马金保.溶栓胶囊的研制及临床应用.中草药,1997,28(9):558.
[62]王冬梅,尚丽彤,翟路.大黄的研究进展.现代商贸工业,2008,20(2): 286~287.
[63]李红江,陈德昌.大黄对烫伤大鼠粘膜上皮细胞肿瘤坏死因子受体基因表达的影响.中国急救医学,2001,21(1):1~3.
[64]徐先祥,夏伦祝,高家荣,等.黄芪总苷和赤芍总苷协同抗血小板作用研究[J].中药材, 2002, 25(9): 653~655.
[65]吴家斌,舒贵扬.赤芍801对肾病综合征患者血脂和血液流变学的影响.中药药理与临床,2001;17(1):45~6.
[66] Hsu FL, Lai CW, Cheng JT. Antihyperglycemic effects of paeoniflorin and 8-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora.Planta Med, 1997;63(4):323~5.
[67]骆苏芳,张佩文,李锐松.虎杖结晶4号对兔血管的舒张作用.第一军医大学学报,1992,12(1):10.
[68]王跃忠,骆苏芳,张佩文,等.3,4,5-三羟基芪-3-D-葡萄糖甙减轻动脉内皮损伤性血栓形成的作用[J].中国药理学报,1995,16(2):159.
[69]上海医药工业研究所中药分析室.虎杖综合利用.医药工业,1976,10:34.
[70]木岛正夫.药用植物大辞典(日) .广川书店,1977:28.
[71]徐承水,王文房.何首乌提取物对大鼠血脂水平的影响.曲阜师范大学学报, 2004,30(3): 85.
[72]徐承水.何首乌提取物对家兔红细胞膜磷脂成分及电泳率的影响.上海中医药大学学报,2000,14(3):57.
[73]刘铁汉,王本样,王毅,等.淫羊藿苷及其肠菌代谢产物对THP-1细胞分泌细胞因子的影响.药学学报,2000,35(4):245~248.
[74]许兰芝,等.淫羊藿总黄酮对肾上腺素能受体阻断作用的研究.中国药理学通报,1994;10(4):311.
[75]王敏,等.淫羊藿甙对血管平滑肌的作用.沈阳药科大学学报,1993;10(3):185.
[76]李锐松,许俊杰.淫羊藿煎剂对健康人血小板聚集性的影响.中药药理与临床,1987;4(4):45~48.
[77]葛淑兰,田景振.淫羊藿及其有效成分的药理研究进展.中国药师,2005, 8(6):462~464.
[78]徐长春,李晓宇,杨军平,等.荷叶生物总碱对肥胖高脂血症大鼠减肥作用的实验研究.江西中医学院学报,2001,23(3):120~121. [79 ]阎君宝,金龙,汪江碧,等.决明子抑制营养性肥胖大鼠体重增加的作用.中药材,2001,27 (4) :281～284.
[80]高小平.中药提取物中α2葡萄糖苷酶抑制剂的筛选.天然产物研究与开发, 2003, 115 (6)∶5 36.
[81]周亚兵.酸味中药复方对2型糖尿病大鼠糖代谢的调节作用.成都中医药大学学报,2004,27 (1)∶1 3
[82] Carey DG.Abdominal obesity.Curr Opin Lipidol,1998,9:35.
[83] Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. ORev, 2000,1(1): 47.
[84]黄峻,刘超,丁国宪.代谢综合征与心血管疾病,北京:科学出版社,2004,1:22.
[85] Lithell HL,Hyperinsulinemia,insulin resistence and treatment of hypertension. Am J HyPertention.1996,9:1508~1548.
[86] Tonkin A.The metabolic syndrome~a growing problem.European Heart Journal Supplements.2004,6:37.
[87] Yoshikawa H,Tajiri Y,Sako Y,et al.Effects of free fatty acidsonβcell functions:a possible involvement of peroxisome proliferators activated receptors or pancreaticduodenal homeobox.Metabolism,2001,50:613~618.
[88] Mu YM,Yanase T,Nishi Y,et al.Saturated FFA,palmiti-acid and stearic acid,induce apoptosis in human granulosacells.Endocrinology,2001,142:3590~3597.
[89] Tripathy D,Mohanty P,Dhindsa S,et al.Elevation of free fatty acids induces inflammation and impairs vascular reactivity inhealthy subjects.Diabetes,2003,52:2882~2887.
[90] Burke JR.Targeting I kappa B kinase for the treatment of inflam-matory and other disorders.Curr Opin Drug Discov Devel,2003,6:720~728.
[91] Sun Y,Liu S,Ferguson S,et al.Phosphoenolpyruvate carboxyki-nase overexpression selectively attenuates insulin signaling andhepatic insulin sensitivity in transgenic mice.J Biol Chem,2002,277:23301~23307.
[92]李卫菊.脂肪因子和代谢综合征.中国分子心脏病学杂志,2007,7(6):366~368.
[93] Van Dielen FM,Van Veer C,Buurman WA,et al. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab,2002,87(4):1708~1716.
[94] Ailhaud G.Adipose tissue as a secretory organ:from adipogenesis to the metabolic syndrome. Comptes Rendus Biologies,2006,32 (8):570~577.
[95] Frühbeck G,Salvador J.Role of adipocytok ines in metabolism and disease.Nutrition Research,2004,24 (10):803~826.
[96] Koh KK,Han SH,Quon MJ. Inflammatory Markers and the Metabolic Syndrome Insights From Therapeutic Interventions.Journal of the American College of Cardiology,2005,46 (11):1978~1985.
[97] Takeshita Y,Takamura T,Hamaguchi E,etal. Tumor necrosis factor-αinduced production of plasm inogen activator inhibitor-1 and its regulation by pioglita zone and cerivastatin in a nonmalignant human hepatocyte cellline.Metabolism,2006,55 (1):1464~1472.
[98] Gonzalez MA, Selwyn AP.Endothelial function, inflammation, and prognosis in cardiovascular disease .The American Journal of Medicine,2003,115 (8): 99~106.
[99] Black PH. The inflammatory consequences of psychologic stress:Relationship toinsulin resistance,obesity,atherosclerosis and diabetes mellitus,type II. Medical Hypotheses,2006,67 (4):879~891.
[100] Yudkin JS,Juhan-Vague I,Hawe E,etal. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease:the HIFMECH study. Metabolism,2004,53 (7):852~857.
[1]刘振平.运动和代谢综合征.中国运动医学杂志,2000,19(2):191.
[2] Tsujinaka K,Nakamura,T Imaeda H,et al. A high lipid Peroxide diet feeding facilities normal rats to insulin resistance andβcell apoptosis.Diabetes,2000,49(suppl 1):A420:1773~po.
[3]程桦.代谢综合征的临床研充进展.新医学,2000;(5) 330~332.
[4] The European Group for the Study of Insulin Resistance (EGIR) .Frequeney of the WHO metabolic syndrome in European cohorts,and an alternative definition of an insulin resistance syndrome.Diabetes Metab,2002,2:354~376.
[5] World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its complication.WHO/NCD/NCS,1999:31~32.
[6] Expert Panel on Detection,Evaluation,and Treatment o f High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program(NCEP) expert panel on detection,evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) .JAMA,2001,285:2486~2497.
[7]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议.中华糖尿病杂志,2004,12(3):156~16.
[8]金文胜,潘长玉.国际糖尿病联盟关于代谢综合征定义的全球共识.中华内分泌代谢杂志,2005,21(4):4b~1~4b~2.
[9]脑卒中、冠心病发病危险因素进一步研究协作组.中国11个省的代谢综合征流行病学调查.中华预防医学杂志,2002,36(5):298.
[10] Anand SS,Yi Q,Gerstein H,et a1.Re1ationship of metabo1ic syndrome and fibrinolytic dysfunction to cardiovaseular disease.Cireulation,2003,108:420~425.
[11] Ford ES,Giles WH,Dietz WH.Prevalence of the metabolic syndrome among us adults:finds from the Third National Health and Nutrition Examination Survey JAMA,2002,287:356~359.
[12]陈蕾,贾伟平,陆俊茜,等.上海市成人代谢综合征流行病学调查.中华心血管病杂志,2003,31:909~912.
[13]孙国祥,周正元,吴国强,等.苏州地区居民代谢综合征流行病学调查.中国慢性病预防与控制,2006,4(3):215~216.
[14]顾东风,Reynolds K,杨文杰,等.中国成年人代谢综合征的患病率.中华糖尿病杂志,2005,13(3):181~186.
[15]朱致惠,汤泰秦.代谢综合征的流行病学调查与分析.暨南大学学报(医学版), 2003,24(2):66~70.
[16]宋克群,李幼阳,肖王兰,等.北京地区老年男性干部人群代谢综合征的流行病学研究.中国老年学杂志,2005,25(10):1150~1152.
[17]张红叶,史秀忠,孙凯,等.代谢综合征患病率及分布特点——青岛港健康研究.高血压杂志,2003,11(1):77~80.
[18]于桂兰,崔会娣,胡国薇.老年代谢综合征患病现状及特点.中国自然医学杂志2005,7(3):196~198.
[19] Storlien LH.Dietary fats and insulin action.16thIDF Congress Abstract and Symposium.1997,Helsinki,Finlnad,P65.
[20]贾伟平,项坤三,陆俊茜,等.局部脂肪及内分泌脂肪调节激素对瘦素水平的影响.中华内分泌代谢杂志,2000,16:70~73.
[21] Burnner EJ,Wunsch H,Marmot MG,What is an opitional diet? Relationship of marcronutirent intake to obesity, glucose toleranee,lipoprotein cholesterol leveol and the metabolic syndrome in the WhitehallⅡstudy [J].Int J Obes Relat Metab Discord,2001,25:45.
[22]祝之明.代谢综合征病因探索与临床实践.第一版.北京:人民军医出版社,2005:36.
[23] Hunt KJ,Heiss G,Sholinsky PD,et al.Familial history of metabolic disorders and the multiple metabolic syndrome:the NHLBI family heart study.Gene Epidemio,2000,19:395.
[24] Vitaliano PP,Scanlan JM,Zhang J,et al.A path model of chronic stress,the metabolic syndrome,and coronary heart disease.Psychosom Med,2002,64(3):418~435.
[25] Raikkonen K,Matthews KA,Kuller LH.The relationship between psychological risk attributes and the metabolic syndrome in healthy women : antecedent or consequence.Metabolism,2002,51(12):1573~1577.
[26]黄峻,刘超,丁国宪.代谢综合征与心血管疾病,北京:科学出版社,2004,1: 22.
[27] Lithell HL,Hyperinsulinemia,insulin resistence and treatment of hypertension. Am J HyPertention.1996;9:1508~1548.
[28] Tonkin A.The metabolic syndrome~a growing problem.European Heart Journal Supplements.2004;6:37.
[29] Stern MP . Diabetes and cardiovascular discase . The“common soil”hypothesis. Diabetes,1995,44(4):396.
[30] Neel JV. Diabetes mellitus: a thrifty genotype rendered detrimental by“progress”? Am J Hum Genet,1962,14;353.
[31] Hales CN,Barker DJP, Clark PMS,et al. Fetal and infant growth and impaired glucose tolerance at age 64,BMJ,1991,303:1019.
[32] Groop LC,et al. J Inter Med,2001,250:105.
[33] McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2diabetes.diabetes,2002,51:7.
[34] Unger RH. Minireview: weapons oflean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology,2003,144(12):5159.
[35]项坤三.代谢综合征的流行病学和病因学.国外医学·内分泌分册,2002,22(5):280.
[36] Kershaw EE,Flier JS. A dipose tissue as an endocrine organ.JClin End oerinol Metab,2004, 89:2548~2556.
[37]田成功,邵加庆,于镔.瘦素:胰岛素抵抗的独立危险因素.中华内分泌代谢杂志,2002,18(3):184~187.
[38] Arita Y ,Kihara S,Ouehi N,et al. Paradoxical decrease of an adipose~specific protein,adiPonectin, in obesity. Biochem BioPhys Res Commun.1999,257(1):79~83.
[39] Masahiro Kumada,Shinji Kihara,Noriyuki Ouchi,et al. Adiponeetin specifically Increased Tissue Inhibitor of Metalloproteinase~1 Through Interleukin~10 Expression in Human Macrophages. Circulation 2004,109:2046~2049.
[40] Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyteprotein adiponectin are decreased in parallel with reduced insulin sensitivity during theprogression to type 2 diabetes in rhesus monkeys.Diabetes,2001,50(5):1126.
[41]李东峰,杨波,杨汉东等.代谢综合征患者血清抵抗素与血脂、肥胖和胰岛素抵抗关系的研究[J〕.中国临床医学,2005,12:206~208.
[42]张艳芳,吴汉妮.抵抗素与胰岛素抵抗.国外医学分子生物学分册,2003,25(5):297~299.
[43]鲁瑾,邹大进,张家庆.肿瘤坏死因子-α致胰岛素抵抗.中国病理生理杂志,1999,15(12):1146~1148.
[44] Hotamisligil GS,Peraldi P,Budavari A,et al. IRS~1~Mediated Inhibition of Insulin RecePtor Tyrosine Kinase Activity in TNF-αand obesity~induced insulin Resistanee [J].Scienee, 1996,271(5249):665~668.
[45] Hube F,Hauner H. The role of TNF-αin Human AdiPose Tissue: Prevention of weight Gain at the ExPense of Insulin Resistance [J],Horm Metab Res,1999,31(12):626~631.
[46]顾鸣宇,盛正妍.胰岛素抵抗与脂肪肝.国外医学内分泌分册,2003,23(增刊):32~33.
[47]余丹箐,高鑫,赵耐青,等.肥胖患者血清C~反应蛋白水平变化与代谢综合征的关系.复旦学报(医学版),2002,29(1):45~49.
[48] Festa AD. Agostino R. Howard G.et al. Chronic subelinical inflammation as part of the Insulin resistance syndrome: the Insulin resistance Atheroselerosis study (IRAS). Circulation,2000,102:44~47.
[49]万惠,郭常辉,唐欣.血浆PAI~1与胰岛素抵抗及脂质紊乱相关性研究【J〕.重庆医学,2005, 34:29~32.
[50]漆泓,孙明,周宏研.MS患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系.临床内科杂志,2003,20(7):353~355.
[51] Bergman RN. Ader M. Free fatty acid and pathogenesis of type 2 diabetes mellitus. TEM,2000, 11:351~356.
[52]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议.中华糖尿病杂志,2004,(12)3:157.
[53]纪立农.国际糖尿病联盟代谢综合征全球共识定义解读.中华糖尿病杂志,2005,(13)3:176.
[54]杜鹃.有氧运动改善胰岛素抵抗综合征的研究进展.国外医学内分泌学分册,2004, 24(5):347~349.
[55] American Diabetes Association.Implication of the United Kingdom Prospective Diabetes Study.Diabetes care,1998,21:2180~2185.
[56] Stephen Smith.罗格列酮改善胰岛素抵抗和β细胞功能及对心血管的潜在保护作用.国外医学内分泌学分册,2002,22(5):284~286.
[57] Girman CJ,Rhodes T,Mercuri M,et al.The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study(4S)and the Airforce/Texas Coronary Atherosclerosis Prevention Study (ATCAPS/Tex CAPS).Am JCardiol,2004,93:136~141.
[58] Pyorala K,Ballantyne C,Lee M,et al.Reduction of coronary events by simvastatin in non–diabetic coronary heart disease patients with and without the metabolicsyndrome : subgroup analysis of the Scandinavian Simvastat in Survival Study.Diabetes,2003,52:A19.
[59] Rubins H B,Robins S J,Collins D,et al.Diabetes,plasma insulin,and cardiovascular disease : subgroup analysis from the Department of Veterans Affairs high~densitylipoprotein intervention trial(VAHIT).Arch Int Med,2002,162:2597~2604.
[60] Yusuf S,Sleight P,Pogue J,et al.Effects of an angiotensin converting enzyme inhibitor,ramipril,on cardiovascular events in high~risk patients.The Heart Outcome PreventionEvaluation Study Investigators.N Engl J Med,2000,342(3):145~153.
[61] Definition of Metabolic Syndrome Report of the National Hean,Lung,and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation,2004,109:42~46.
[62] Grundy SM,Brewer B,Clecman JI,et al.Definition of metabolic syndrome.Report of the National Heart,Lung,and Blood Institute/American Heart Association Conference on Scientific Issue Related to Definition.Circulation,2004,109:433~438.
[63]徐远.中医治疗代谢综合征的思路与方法.中医杂志,2003;44(4):301.
[64]张志玲,李惠林,张黎群,等.活血降糖饮治疗代谢综合征30例疗效观察.中医药临床杂志,2004,16(4):327~328.
[65]刘敏.2型糖尿病患者胰岛素抵抗的中医实质初探.中国中医药杂志, 2004, 2(1): 14~16.
[66]倪永骋.老年人胰岛素抵抗综合症病因病机探讨.中医药学刊,2003,21(6): 963.
[67]董卫.综合治疗胰岛素抵抗综合征56例.山西中医,2004,20(6):17.
[68]张京春,陈可冀.代谢综合征与中西医结合综合干预.中国中西医结合杂志2004;24(11):1029~1032.
[69]张晓燕,宋鲁成.试论肝脾与代谢综合征的关系.山东中医药大学学报,2005;29(1):20.
[70]胥改珍.从痰瘀论治代谢综合征.山西中医,2003,19(4):61~62.
[71]刘林,吕文亮.2型糖尿病发病机理与湿热关系的探讨,湖北中医学院学报,2004, 6(1): 29~30.
[72]于顾然,贺燕勤,郭云庚,等.冠心病中医证型于胰岛素抵抗、脂质及红细胞膜ATP酶关系的临床研究.中医杂志,2000,41(2):111~112.
[73]李东晓.痰与代谢综合征.中国中医基础医学杂志,2005,11(2):144~145.
[74]袁长武,王建清.代谢综合证中医证型与白介素~6相关性研究.新疆中医药,2008,26(2):24~28.
[75]袁肇凯,黄献平,简亚平,等.高脂血症痰瘀证候与胰岛素抵抗的关系.中国医药学报,2003,18(8):468~470.
[76]王文健.代谢综合征的中西医结合防治.中西医结合学报,2004,2(5):393,395.
[77]刘承琴,赵建群.2型糖尿病胰岛素抵抗重视从脾论治的思路.新中医,2003,35(9): 28~29.
[78]李锡杰,刘志龙.论从脾论治代谢综合征.中医药导报,2006,12(4):9~11.
[79]将卫民,唐蜀华,陈晓虎,等.高血压病辨证分型与胰岛素抵抗的初步研究.中医杂志,1999,40(1):45~46.
[80]王智明.胰岛素抵抗从肝论治的探讨.光明中医,2003,(18)6:13~14.
[81]王德玉,徐志瑛.论肝与代谢综合征.浙江中西医结合杂志,2004,14(1):23~24.
[82]董卫.综合治疗胰岛素抵抗综合征56例.山西中医,2004,20(6):17.
[83]张晓燕,宋鲁成.试论肝脾与代谢综合征的关系.山东中医药大学学报,2005, 29(1):20.
[84]杨文军,庄严.胰岛素抵抗综合征辨治初探.山东中医药大学学报,2002,26(4):275~276.
[85]张德贵,贺建丽.调肝滋肾法治疗胰岛素抵抗及其相关性疾病之临证与探讨.光明中医,2002,17(4):26~27.
[86]张慧,郭宏敏.中药养阴和瘀方对老年代谢综合征胰岛素抵抗及高凝血症的干预作用的研究.中国老年保健医学杂志,2006,4(3):50~52.
[87]吴深涛.对胰岛素抵抗宜用益肾化瘀、疏利少阳法.中医杂志,2001,42(6):332~333.
[88]张玉金,张文艺.高血压病辨证分型和胰岛素抵抗关系的探讨.河南中医,2001,21(1):36.
[89]叶子,张世珍.代谢综合征的中医认识和治疗.中国中西医结合杂志,2005;25(7): 599.
[90]王亚红,郭维琴.高脂血症中医临床研究述评[J].中国中医基础医学杂志,2001,7(10):71.
[91]梁兴伦,韩明向.胰岛素抵抗模型大鼠的中医证候研究[J].中国中西医结合杂志,2001,21(7):528~530.
[92]常宗范,冯奕超.胰岛素抵抗的中医辨证论治.吉林中医药,2001,(3):54~55.
[93]王琦,李英帅.中医对代谢综合征的认识及辨治探讨(下).浙江中医杂志,2006,41(11):623~625.
[94]肖月星,林兰,等.代谢综合征的中医认识和诊疗思路.中国中医基础医学杂志,2007;13(7):538~539.
[95]仝小林,张志远.中医对代谢综合征的认识和治疗.中医杂志,2002;43(9):708~709.
[96]熊曼琪,林安钟,朱章志,等.加味桃核承气汤对Ⅱ型糖尿病大鼠胰岛素抵抗的影响.中国中西医结合杂志,1997,17(3):165~168.
[97]蓝元隆,周国英.气虚痰浊血瘀与2型糖尿病胰岛素抵抗地关系.中国医学理论与实践,2004,(1):20.
[98]候振民,李玉明,李振有,等.“糖脂消”对代谢综合征的疗效研究.Medical Journal of the Chinese People’s Armed Police Forces,2004,15(1):15~18.
[99]潘玲,冯全生.八味丸方药对代谢综合征患者治疗效应的临床观察.四川生理科学杂志2005,27(2):87~91.
[100]管弦,黄菲,吴纪祖,等.六味地黄丸银杏叶片对早期2型糖尿病胰岛素抵抗与脂毒性的影响.辽宁中医杂志,2006,33(11):1423~1426.
[101]李莉芬,吴玉红.金芪降糖片治疗2型糖尿病胰岛素抵抗患者的观察.天津医药,2006,34(9):654~656.
[102]陈苹,朱章志,郎江明,等.益气养阴活血通腑法治疗2型糖尿病磺脲类药继发性失效的临床观察.中国中西医结合杂志,2004,11(7):585~588.
[103]于炳信.新消渴胶囊治疗2型糖尿病及胰岛素抵抗综合征的临床报告.中华现代临床医药杂志,2003,4(1):7~9.
[104]陈维铭,王馨然.半夏白术天麻汤对单纯性肥胖患者胰岛素抵抗的影响.现代中西医结合杂志,2004,13(2):351~353.
[105]喻红,邹先智.地黄饮子对改善糖尿病胰岛素抵抗的疗效观察.湖南中医药导报,2001,7(1):19.
[106]仝小林,柳红芳,朴信映,等.开郁清胃颗粒治疗Ⅱ型糖尿病胰岛素抵抗的临床研究.实用中医内科杂志,2001,15(2):10~11.
[107]袁肇凯,黄献平,田松,等.养心通脉片对胰岛素抵抗综合征血脂及甲襞微循环的影响.湖南中医学院学报,2003,23(4):35~38.
[108]刘英华,陈春梅,赖育红,等.通心络改善糖尿病冠心病患者胰岛素抵抗的观察研究.天津中医药,2006,23(4):282~283.
[109]钱秋海,庄乾竹.愈胰饮治疗胰岛素抵抗综合征的临床研究.中国中医药信息杂志,2002,9(7):12~14.
[110]卢立广,叶子,滋阴清心汤治疗代谢综合征63例观察.浙江中医杂志,2005,(3):200.
[111]安其,李朝敏,程斌.安一胶囊治疗胰岛素抵抗综合征的临床观察.成都中医药大学学报,2003,25(1):10~12.
[112]刘宪俊,杨叔禹,陈弼沧,等.平糖胶囊对气阴两虚型2型糖尿病患者胰岛素抵抗干预的研究.福建中医药,2006,37(4):3~5.
[113]谭鳗娜,林溢涛等.自拟消抵汤治疗代谢综合征30例临床观察.基层医学论坛,2006,10(4):337~338.
[114]宋镇星.调谢胶囊治疗代谢综合征疗效观察.辽宁中医杂志,2006,33(10):1294~1295.
[115]戴飞跃,黄保民,唐晨光,等.福寿降糖饮治疗2型糖尿病胰岛素抵抗的临床观察.中医药学刊.2006,24(8):1497~1498.
[116]徐云生,杜丙会.中西医结合治疗X综合征30例.山东中医杂志,1998,17(5):224.
[117]唐蜀华,蒋卫民,陈晓虎,等.针箭颗粒改善高血压病胰岛素抵抗的临床研究.中国中西医结合杂志,2000,20(7):511~514.
[118]姜淼.三黄安消胶囊治疗2型糖尿病及改善胰岛素抵抗作用的临床研究.新中医,2006,38(1):28~30.
[119]卢晓琳.益气养阴活血通腑法治疗胰岛素抵抗综合征52例.河北中医,2003,25(4):270~271.
[120]张慧,郭宏敏.中药养阴和瘀方对老年代谢综合征胰岛素抵抗及高凝血症的干预作用的研究.中国老年保健医学杂志,2006,4(3):50~52.
[121]崔琳琳,赵晓华,李丽,等.小檗碱对高脂膳食大鼠胰岛素抵抗的早期干预实验研究.中西医结合心脑血管病杂志,2005;3(3):230.
[122]林佳,潘竞锵,李博薄,等.黄连对D~半乳糖诱导大鼠血糖和糖耐量减退影响的实验研究.中国临床医药研究杂志,2005,(139):15045~15047.
[123]倪艳霞,刘安强,高云峰,等.黄连素治疗Ⅱ型糖尿病60例疗效观察及实验研究.中西医结合杂志,1988,8(12):711~712.
[124]陈其明,谢明智.黄连及小檗碱降血糖的研究.药学学报,1986,21(6):401.
[125]鲁瑾,邹大进,张家庆.黄芪预防肝瘤坏死因子-α所致胰岛素抵抗.中国中西医结合杂志,1999,19(7):420~422.
[126]李志荣.黄芪多糖冲剂治疗Ⅱ型糖尿病的临床研究.山西医药,1995,11(11):16.
[127]江清林,李延军,辛华.黄芪对胰岛素、C肽分泌作用研究.黑龙江医药科学,1999,22(3):24~27.
[128]黄春玲,吕玉萍.黄芪辅助治疗2型糖尿病对胰岛素抵抗的影响.中国中西医结合杂志,2003,23(10):779~780.
[129]黄琦,许家鸾.麦冬多糖对2型糖尿病血糖及胰岛素抵抗的影响.浙江中西医结合杂志,2002,12(2):81~82.
[130]王钦茂,刘超,赵帜平,等.丹皮多糖降血糖有效成分的筛选及其作用研究.中国中医基础医学杂志,2001,7(5):18~21.
[131]赵瑛,李蔚,祖莹.葛根素对试验性代谢综合征大鼠血脂影响的研究.中国中医药科技,2007,14(l):29~30.
[132]张妍,毕会民,甘佩珍.葛根素对胰岛素抵抗大鼠骨骼肌中蛋白激酶B表达影响.中国药理学通报,2004,20(3):307~310.
[133]李娟娟,毕会民.葛根素对胰岛素抵抗大鼠脂肪细胞葡萄糖转运蛋白4的影响.中国临床药理学与治疗学,2004,9(8):885~888.
[134]黄燕飞,刘志红,陈惠萍,等.大黄酸和罗格列酮对db/db糖尿病小鼠代谢紊乱和肾脏损伤的作用比较.肾脏病与透析肾移植杂志,2004,13(3):215~221.
[135]董卫,巫奕丽.胰岛素抵抗的针药治疗.中国临床医生, 2003, 31(1): 59.
[136]刘志诚,孙凤岷,朱苗花,等.针灸对非胰岛素依赖性糖尿病胰岛素抵抗的影响.上海针灸杂志,2000,19(1):5~7.
[137]谌剑飞,马雅玲,蔡绍华,等.针刺对糖尿病的抗凝与逆转胰岛素抵抗作用.上海针灸杂志,2001,20(4):5~7.
[138]唐胜修.头穴对中风后遗症患者胰岛素抵抗的调整作用研究.安徽中医临床杂志,~28~化瘀降浊合剂干预代谢综合征的疗效评价及其对部分致动脉粥样硬化因子的影响2002,14(3):164~165.
[139]魏群利,刘志诚.针刺配合耳穴压籽治疗2型糖尿病(肥胖型)67例.安徽中医学院学报,2002,21(3):34~37.
[140]秦福兰,贾杰,郭学军.针刺和运动疗法对2型糖尿病的疗效观察.中国针灸,2002,22(9):579~581.
[141]张智龙,薛莉,吉学群,等.针刺对2型糖尿病胰岛素抵抗影响的临床研究.中国针灸,2002,22(11):723~725.
[142]胡葵,李嘉,刘志诚.针灸治疗肥胖型2型糖尿病的临床研究.上海针灸杂志,2001,20(4):8~10.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |